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Abstract
OBJECTIVES: Post-operative atrial ﬁbrillation (POAF) is the commonest post-operative cardiac arrhythmia, affecting1 in 3 patients under-
going coronary artery bypass grafting (CABG). Although its aetiology is complex, atrial substrate changes may pre-dispose to its onset. This
study aims to ascertain the atrial microRNA signature of POAF and determine the potential for circulating microRNA as a pre-operative
biomarker for this arrhythmia.
METHODS: Thirty-four patients undergoing non-emergent, on-pump CABG were prospectively recruited. Right atrial biopsies were taken
intra-operatively and snap frozen for RNA extraction. Plasma was obtained at 24 h pre-operatively and at 2 and 4 days post-operatively.
POAF was deﬁned by continuous Holter recording. Inter-group comparisons were performed using Student’s t-test or analysis of variance
as required. Receiver operating characteristic (ROC) analysis was used to determine the diagnostic accuracy of pre-operative serum miRNA
as a POAF biomarker.
RESULTS: Sixteen microRNAs were differentially expressed in the atrial myocardium of POAF patients when compared with those main-
taining sinus rhythm. miR-208a was the most underexpressed [fold change (FC) = 2.458] and miR-483-5p the most overexpressed
(FC = 1.804). miR-483-5p also demonstrated signiﬁcant overexpression in the pre-operative serum of these patients, with ROC analysis
demonstrating an overall predictive accuracy of 78%.
CONCLUSIONS: This study provides the ﬁrst description of atrial myocardial and circulating plasma microRNA in POAF patients. Our ﬁnd-
ings suggest POAF may be associated with pre-existing atrial substrate differences predisposing to arrhythmogenesis. Moreover, this study
highlights the potential for miR-483-5p in biomarker development. Further work must now perform prospective, targeted validation of
these results in a larger patient cohort.
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INTRODUCTION
De novo post-operative atrial ﬁbrillation (POAF) affects 1 in 3
patients undergoing cardiac surgery leading to increased post-
operative hospital stay, morbidity and mortality [1, 2]. Furthermore,
POAF may also produce signiﬁcantly worse long-term outcomes [3,
4], with evidence to suggest that 10-year mortality may be up to
48% higher in patients developing POAF when compared with
those remaining in sinus rhythm (SR) [5].
POAF results from a complex interaction of ‘triggering’ stimuli
and ‘sustaining’ mechanisms acting on a pro-arrhythmogenic
myocardial substrate. While much investigation has focused on
the stimulus for POAF, the make-up or indeed existence of any
predisposing atrial substrate remains poorly understood.
First discovered in 1993 [6], microRNAs are small non-coding
RNA molecules 19–25 nucleotides in length that suppress their
target mRNA by inhibiting translation or promoting degradation.
Although some are tissue speciﬁc, microRNAs are also present in
the circulating blood, which derived from endothelial cells, plate-
lets, mononuclear phagocytes or dead and dying cells. Circulating
miRNAs are remarkably stable through carriage in apoptotic bodies
and microvesicles, or binding to Argonaute 2 protein (Ago2)
demonstrates resistance to endogenous RNases. As a result, they
hold the potential to exert paracrine effects and even speciﬁcally
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deliver miRNA to their target cells [7]. However, the low concentra-
tion of paracellular miRNA detectable in human plasma and other
bioﬂuids as well as the common expression between blood cells
and the organ/disease of interest has previously led to difﬁculty in
interpreting the signiﬁcance of circulating miRNA particularly in the
context of biomarker discovery [8].
The role of miRNA in cardiac arrhythmogenesis is becoming in-
creasingly apparent. miRNA targeting pathways associated with
the regulation of cardiomyocyte metabolism (miR-208a and
miR-223) may alter the provision of energy substrate required to
maintain AF [9–11], whereas other miRNAs are thought to play a
central role in changes associated with structural (miR-133,
miR-590, miR-29b, miR-208, miR-638 and miR-150) and electrical
remodelling (miR-328, miR-1 and miR-26) [12]. However, much of
the work to date examines miRNA expression in right or left atrial
tissue and there remains a paucity of evidence surrounding circu-
lating microRNA in human AF [13, 14]. Furthermore, current
studies address the circulating miRNA signature in long-standing
and paroxysmal AF and do not examine the role of miRNA in the
new onset post-operative form of this arrhythmia.
The purpose of this study is therefore to ascertain whether the
atrial microRNA signature is altered in AF naive patients develop-
ing de novo post-operative AF. Furthermore, we aim to determine
whether POAF is associated with any changes in circulating
microRNA expression that may be detected pre-operatively,
giving rise to the potential for biomarker development and a sub-
sequent novel pre-operative risk stratiﬁcation system in this highly
prevalent and troublesome post-operative arrhythmia.
METHODS
Patient selection and recruitment
The study was approved by the local and regional research ethics
committee (Ref: 09/H0711/23). Between November 2010 and
September 2011, 34 patients undergoing non-emergent, on-pump
coronary artery bypass grafting (CABG) at Imperial College
Healthcare NHS Trust were prospectively selected to participate in
this study and informed consent obtained. Emergency cases, those
requiring adjunctive procedures (e.g. valve repair or replacement),
patients with a prior history of any cardiac arrhythmia, thyroid
disease, those taking anti-arrhythmic agents or undergoing surgery
with mini-cardiopulmonary bypass systems were excluded.
All patients underwent continuous Holter (Novocor Vista 5 lead
system, 2 channel recording) monitoring from the time of admis-
sion to the time of surgery (12–24 h). Post-operatively, all patients
were monitored with the same Holter devices from the time of
surgery to the time of discharge. Atrial ﬁbrillation was deﬁned
according to Heart Rhythm Society Guidelines [15]. POAF was
deﬁned as new onset AF following CABG surgery in patients with
pre-operative Holter recordings demonstrating SR and no prior
history of the arrhythmia. All episodes of AF, atrial ﬂutter or tachy-
cardia of at least 30 s duration were documented. Only AF episodes
>30 s were categorized as AF positive (Group 2) [15]. Patients were
grouped retrospectively (following Holter analysis after discharge)
according to the absence (Group 1) or presence (Group 2) of POAF.
Sampling
Right atrial tissue biopsies were taken intra-operatively prior to
instigation of cardiopulmonary bypass from the right atrial
cannulation site. Whole blood samples were obtained at 24 h pre-
operatively and at 2 and 4 days post-operatively. Plasma was
extracted from whole blood by centrifugation at 5000 g for 6 min
and aliquots stored at −80 °C until use.
Laboratory methods
RNA extraction. Whole RNA was extracted from atrial tissue
using TRIZOL® reagent as described previously [16]. RNA quality and
concentrations were assessed using the Nanodrop 1000
spectrophotometer and Agilent 2100 Bioanalyser. All RNA integrity
numbers (RIN) were >7.5.
miRNA microarray. Microarray analysis was performed using the
Agilent 60k microarray platform according to the manufacturer’s
protocol [17]. Spike in solution derived from drosophila sequences
was used to distinguish biological data from processing derived
changes. One hundred nanaograms of total RNAs were ligated and
ﬂuorescently labelled with cyanine dye (pCp-Cy3) at its 30 end.
Labelled RNAwas puriﬁed and dried prior to hybridization. Samples
were loaded onto pre-prepared 8 × 60k MicroArray Slides (Agilent)
and hybridized using the Agilent Sure-hyb hybridization chamber
for 20 h at 55 °C. Following completion of hybridization, slides were
scanned using the Agilent G2505C MicroArray Scanner and feature
extraction performed using the Agilent Feature Extraction Software
version 10.7.3.1. Analysis was performed using Agilent GeneSpring
software GX11.0. A fold change (FC) cut-off of >1.5, at the P < 0.05
signiﬁcance level, was set to detect miRNA differentially expressed
between groups.
Quantitative reverse transcription polymerase chain
reaction. miRNA changes were veriﬁed using speciﬁc TaqMan™
qPCR microRNA assays according to the manufacturer’s protocol
(Taqman, Applied Biosystems, Life Technologies, Paisley, UK). For
each study probe, identical quantitative reverse transcription
polymerase chain reactions were also carried out using a control
gene (miRNA-186), which was shown to be experimentally
consistent across all samples in microarray analysis.
All reactions were carried out in three technical replicates using
the Applied Biosystems 7500 fast Real-Time PCR System [18].
Ampliﬁcation plots were examined for adequate ampliﬁcation
and successful polymerase chain reaction. A ΔRn threshold value
of 0.2 (within the exponential phase of ampliﬁcation) was set to
ensure comparability across plates. Ct values were recorded for
both samples and controls and compared using the ΔΔCt method.
Statistical analysis. Inter-group comparisons were performed
using Student’s t-test if two groups or one-way analysis of variance
if multiple groups. Statistical signiﬁcance was reported if P < 0.05.
Receiver operating characteristic (ROC) analysis was used to
determine the diagnostic accuracy of pre-operative serum miRNA
as a diagnostic biomarker for POAF. All calculations were
performed using Prism (Graphpad, La Jolla, CA, USA).
RESULTS
Thirty-four patients undergoing non-emergent, on-pump CABG
were recruited. Twenty-one patients did not develop POAF and were
classiﬁed into Group 1, and 13 patients developed POAF and were
classiﬁed into Group 2. The mean time to onset of AF was 2.5 days.
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Pre-operative demographics
A summary of the pre-operative demographics is shown in Tables 1
and 2. No statistically signiﬁcant differences were observed in any
demographics or cardiovascular risk factors studied. Furthermore,
no signiﬁcant differences were seen between the groups in terms of
β-blocker use or pre-operative echocardiographic parameters
(Supplementary Table 1).
miRNA microarray
A cohort of 22 matched samples (11 AF and 11 nAF) determined
to have an RIN >7.5 were selected for miRNA microarray analysis.
Based on a cut-off for signiﬁcance at a FC of 1.5 and a P-value of
<0.05, 16 miRNAs were differentially expressed between Groups 1
and 2. Of these, hsa-miR-483-5p was found to be the most
up-regulated mature miRNA (FC = 1.804) and hsa-miR-208a the
most down-regulated (FC = 2.458) (Table 3).
Quantitative reverse transcription polymerase
chain reaction
In light of the differential expression in atrial tissue miRNA between
groups, expressions of hsa-miR-483-5p and hsa-miR-208a were
Table 1: Pre-operative demographics: cohort of patients
in atrial tissue microarray experiments
AF (n = 11) nAF (n = 11) P-value
Gender (% male) 73% 82% 0.193
Age (years) 63.3 ± 3.08 59.6 ± 3.62 0.452
BMI (kg/m2) 30.5 ± 2.29 27.1 ± 1.09 0.210
Height (m) 1.61 ± 0.07 1.72 ± 0.02 0.178
Weight (kg) 79.8 ± 4.31 81.3 ± 3.29 0.795
MI 27% 36% 0.647
Stroke 0.0% 18% 0.138
PVD 9.1% 9.1% 1.000
PCI 0.0% 0.0% 1.000
Hypertension 73% 73% 1.000
Hypercholesterolaemia 91% 91% 1.000
Family history 45% 36% 0.653
Diabetes 55% 55% 1.000
On insulin 27% 45% 1.000
Smoking 18% 27% 0.611
Alcohol >10 U per week 18% 36% 0.338
AF: atrial fibrillation; BMI: body mass index; MI: myocardial infarction;
PVD: peripheral vascular disease; PCI: percutaneous coronary
intervention.
Table 2: Pre-operative demographics: all patients in
serum quantitative reverse transcription polymerase chain
reaction experiments
AF (n = 13) nAF (n = 21) P-value
Gender (M/F) 9/4 15/6 0.716
Age (years) 64.6 ± 11.3 59.6 ± 12.1 0.237
BMI (kg/m2) 30.2 ± 6.14 27.5 ± 3.41 0.247
Height (m) 1.62 ± 0.19 1.67 ± 0.08 0.475
Weight (kg) 80.1 ± 3.86 77.7 ± 2.69 0.623
MI 33% 24% 0.555
Stroke 8.3% 14% 0.614
PVD 17% 4.8% 0.252
PCI 0.0% 0.0% 1.000
Hypertension 75% 76% 0.939
Hypercholesterolaemia 92% 90% 0.909
Family history 45% 65% 0.291
Diabetes 58% 43% 0.392
On insulin 25% 24% 0.939
Smoking 17% 24% 0.629
Alcohol >10 U per week 25% 25% 1.000
AF: atrial fibrillation; BMI: body mass index; MI: myocardial infarction;
PVD: peripheral vascular disease; PCI: percutaneous coronary
intervention.
Table 3: Summary of microarray findings demonstrating
16 miRNAs differentially expressed between Group 1 (n = 11
SR) and Group 2 (n = 11 POAF) in atrial tissue
miRNA P-value Absolute fold
change (FCa)
Regulation
hsa-miR-1202 0.0448 1.6767 Up
hsa-miR-150 0.0109 1.6919 Up
hsa-miR-19a 0.0400 1.6059 Down
hsa-miR-208a 0.0205 2.4580 Down
hsa-miR-223 0.0464 1.6014 Up
hsa-miR-24-1* 0.0134 1.8085 Down
hsa-miR-2861 0.0343 1.5234 Up
hsa-miR-29b 0.0298 1.7646 Down
hsa-miR-301a 0.0319 1.6051 Down
hsa-miR-3141 0.0178 1.5238 Up
hsa-miR-3679-5p 0.0328 1.7947 Up
hsa-miR-4298 0.0248 1.6312 Up
hsa-miR-483-5p 0.0193 1.8036 Up
hsa-miR-572 0.0197 1.6868 Up
hsa-miR-638 0.0353 1.5246 Up
kshv-miR-K12-3 0.0250 1.5513 Up
POAF: post-operative atrial fibrillation.
Figure 1: Expression of hsa-miR-483-5p in pre-operative serum (Group 1:
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also examined in human serum at the following time points: (i) pre-
operatively, (ii) 48 h post-operatively and (iii) 96 h post-operatively.
hsa-miR-208a is a cardiomyocyte-speciﬁc microRNA and was
not detected in the serum at any time point (data not shown).
hsa-miR-483-5p was found to be signiﬁcantly higher in the pre-
operative serum of Group 2 (POAF) when compared with Group 1
(SR) (P = 0.0137) (Fig. 1). No signiﬁcant difference was observed in
the serum expression between POAF and SR groups at 48-h
(P = 0.1991) or at 96-h (P = 0.8040) time points (Fig. 2).
Figure 2 also demonstrates the change in miR-483-5p expres-
sion over time. There was a signiﬁcant increase in the expression
of miR-483-5p comparing pre-operative and 48-h time points in
Group 2 (POAF) (P = 0.046); however, there was no signiﬁcant
change in expression between these time points in Group 1 (SR)
(P = 0.9507). Both groups demonstrated a signiﬁcant increase in
miR-483-5p expression between 48 and 96 h post-operative time
points (POAF: P = 0.0051; SR: P = 0.0055).
Developing a serum test for post-operative
atrial ﬁbrillation
ROC analysis revealed hsa-miR-483-5p levels to have a sensitiv-
ity and speciﬁcity of 77.78 and 77.27, respectively, with a likeli-
hood ratio of 3.422 for the prediction of post-operative AF
when a FC cut-off of 1.262 was used for the expression level of
miRNA-483-5p. The area under the curve (AUC) was 0.78
(Fig. 3).
DISCUSSION
The potential for microRNA to act as non-invasive molecular bio-
markers of systemic disease is of great interest owing to their high
level of stability in many different bioﬂuids including serum,
plasma and urine [19]. As such, by means of a simple blood test
performed at the time of routine patient assessment, quantitation
of a single or cluster of microRNAs may provide a novel avenue
for detection and risk prediction of systemic disease with minimal
disturbance to the patient.
The underlying pathophysiology of atrial ﬁbrillation is complex,
and a combination of structural myocardial changes, alterations in
Figure 2: Scatter plot demonstrating expression levels of microRNA-483-5p at three different time points: pre-operatively, 48-h post-operatively and 96-h post-
operatively. Large crosses and trend line demonstrate mean ΔΔCt values over time separated according to the presence or absence of POAF. P-values denote results
of signiﬁcance testing (Mann–Whitney) between AF and non-AF groups at each time point. AF: atrial ﬁbrillation; POAF: post-operative atrial ﬁbrillation.
Figure 3: Receiver operating characteristic (ROC) curve of pre-operative
hsa-miR-483-5p as a biomarker for post-operative atrial ﬁbrillation (AF).
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the extracellular environment, intracellular ion ﬂux and systemic cir-
culatory factors is likely to underlie the pro-arrhythmogenic sub-
strate [20]. Post-transcriptional regulation of target genes by miRNA
may provide one mechanism by which these processes may be
regulated, disrupting cellular homeostasis and precipitating arrhyth-
mia. Indeed, recently Liu et al. identiﬁed circulating microRNA-150
to be signiﬁcantly underexpressed in the serum of 60 prospectively
collected patients with both paroxysmal (n = 30; FC 17) and per-
sistent (n = 30; FC 20) AF when compared with healthy controls
(n = 30), demonstrating miR-150 to be an independent predictor of
AF (OR: 1.96; 95% CI: 1.5, 3.57; P < 0.001). However, miRNA-150
levels were not able to differentiate paroxysmal from persistent AF
(OR: 1.02; 95% CI: 0.82, 1.13; P = 0.61) [13]. Dawson et al. also
demonstrated a signiﬁcant down-regulation of miR-29b in both the
plasma (n = 30SR, 33 AF) and right atrial appendage tissue of
patients with paroxysmal (n = 9) and chronic atrial ﬁbrillation (n = 8)
with a subsequent reduction in suppression of ﬁbrilin and the colla-
gen (COL1A1 and COL3A1) mRNA transcripts promoting atrial ﬁ-
brosis, structural remodelling and increasing the susceptibility to
re-entry and atrial ﬁbrillation [14].
This study for the ﬁrst time examines the role of miRNA in the cir-
culating plasma of POAF and our results provide the ﬁrst documen-
ted insights into the microRNA signature of this condition. Sixteen
microRNA exhibit signiﬁcant differential expression in the atria of
POAF patients, of which miR-208a is the most down-regulated and
miR-483-5p the most up-regulated mature microRNA. miR-483-5p
is also expressed at signiﬁcantly higher levels in the pre-operative
serum of AF naive patients going on to develop de novo AF in the
post-operative period. The expression of this miRNA then nor-
malizes to that of patients without dysrhythmia by 48 h after
surgery. Furthermore, at a cut-off FC of 1.26, ROC analysis reveals a
diagnostic accuracy of 78% (AUC: 0.78) when this biomarker is used
to predict patients developing POAF. This compares favourably with
previously described pre-operative biomarkers such as pro-BNP,
C-reactive protein and peripheral blood white cell count, which
have been reported to have diagnostic accuracies of 61, 68 and
69%, respectively, when predicting POAF [21–23].
MicroRNA 483-5p is a 22-nucleotide (AAGACGGGAGGAAA
GAAGGGAG) intronic mature microRNA typically transcribed with
its host gene, IGF2, located on chromosome 11p15.5 [24]. It has
been isolated in several human tissue types including myocar-
dium, hepatic and brain tissue as well as in blood serum [24, 25].
At present, miR-483-5p remains relatively poorly examined and
there are no studies reporting on the use of circulating miR-483-5p
as a serum biomarker. Furthermore, the mechanism by which this
microRNA regulates or is modulated by the clinical phenotype of
POAF remains undetermined. Recent work by Morley-Smith et al.
[26] has demonstrated an acute and sustained increase in circulat-
ing mir-483-3p (which originates from the opposite arm of the
same pre-miRNA as miR-483-5p) in heart failure patients after
left ventricular assist device insertion, mirroring suppression of
NT-pro-BNP secretion. Alongside our results, these ﬁndings may
suggest that transcription of serum pre-miRNA-483 may be stimu-
lated in states of cardiac stress, the mature products of which may
then be detected in the systemic circulation. It should also be
considered however that increased miR-483 may represent a by-
stander effect rather than a direct miRNA-mediated mechanism
of POAF pathogenesis. Indeed, the low concentration of para-
cellular miRNA detectable in human plasma argues against a sub-
stantial paracrine function particularly given the one-to-one
nature of microRNA–mRNA interaction that typically requires
high levels of intracellular microRNA [27]. It is therefore possible
that the observed increase in miR-483-5p expression represents
up-regulation of its host gene IGF2, which, for example, may be
stimulated in an attempt to drive cardiac regeneration in states of
cardiac stress. Overexpression of IGF2 may also play a role in pro-
viding a pro-inﬂammatory substrate through the regulation of
NF-kB- and IL-6-mediated pathways, which may in turn lower the
threshold on which a surgical trigger may potentiate AF in the
post-operative period [28]. As such, the exact mechanistic role of
miR-483-5p beyond its use as a simple biomarker requires further
investigation with examination not only of this miRNA but also of
its host gene transcription and protein expression.
Limitations
It is important to consider a number of limitations when inter-
preting these results. First, although the rigorous nature of this trial
provides a robust deﬁnition of POAF with prospectively collected
data, the numbers of patients recruited remain small and further
validation is required in a larger patient cohort. Second, continu-
ous post-operative Holter monitoring for AF was limited to the
in-hospital period and as such asymptomatic AF occurring beyond
this time point may have remained undetected. Third, AF is a
complex, multifactorial arrhythmia and microRNA dysregulation
alone is unlikely to be the sole regulatory mechanism underlying its
pathogenesis. Furthermore, although every attempt was made to
match for environmental disparities, confounding factors such as
electrolyte imbalance, post-operative sepsis (clinical or sub-clinical)
and pharmacological therapies may all inﬂuence the relative ex-
pression of microRNA and the regulation of subsequent biological
pathways. Finally, common miRNA expression between blood cells
and the organ/disease of interest may also lead to difﬁculty in inter-
preting the signiﬁcance of circulating miRNA particularly in the
context of biomarker discovery [8].
CONCLUSIONS
This work has identiﬁed potential pre-existing microRNA dysregu-
lation in patients subsequently developing POAF, particularly
demonstrating underexpression of miR-208a and overexpression
of miR-483-5p in the right atrium of POAF patients. In order to
understand the signiﬁcance of these changes, it is now pertinent
to clarify the potential mechanisms by which these miRNA may
regulate cardiac conduction.
In addition, this study has provided the ﬁrst documented de-
scription of circulating microRNA in POAF patients. Indeed, the
observed differential expression of miRNA-483-5p in both the right
atrial tissue and circulating plasma of these patients supports the
hypothesis of a pre-existing atrial or systemic inﬂammatory sub-
strate to this condition, highlighting the potential for biomarker de-
velopment. Given these ﬁndings, it is now necessary to address the
potential mechanisms behind these changes and validate these
ﬁndings. Prospective, targeted validation of these results in a larger
patient cohort is now required in order to determine the reliability
of circulating microRNA-483-5p as a biomarker for POAF.
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